Overview
Top Medical Research Studies
Throughout the study, we assessed the severity of depression using the Hamilton Rating Scale for Depression (HRSD). What we found was promising. The group taking EPA experienced significantly lower HRSD scores at various checkpoints—specifically at weeks 4, 6, 8, and 12—indicating a reduction in depressive symptoms. Although the rates of remission and response were higher in the EPA group compared to the placebo group, these findings did not achieve statistical significance.
Overall, while EPA shows potential as a treatment for depression, further research is needed to solidify its role. Our findings suggest that it may be an alternative option for MDD patients seeking additional treatment pathways.
Throughout the study, we measured depression levels using the Hamilton Rating Scale for Depression (HRSD). Our results were intriguing—those taking the DHA showed significant improvements in their depression scores compared to the placebo group by weeks 4, 6, 8, and 12. While we noted that 26.7% of participants receiving DHA achieved remission by week 12, this was not statistically significant in comparison to the placebo group.
Overall, our findings support the idea that DHA may serve as a promising alternative treatment for individuals suffering from MDD. Although the results are encouraging, we recognize the need for further research to confirm these benefits conclusively.
Results showed that those taking omega-3 had lower depression scores at various points throughout the study. While there were hints of improved outcomes in terms of remission and response rates, these weren't statistically significant.
Overall, omega-3 fatty acids could be a promising alternative, but further research is necessary to confirm their effectiveness.
Most Useful Reviews
Medical Researches
- All Researches
Both EPA and DHA were shown to reduce myelin damage and support the health of oligodendrocytes, but EPA led to more significant improvements. We noted higher levels of essential proteins related to myelin repair alongside reduced lipid peroxidation in the presence of EPA.
Notably, both compounds inhibited inflammation pathways associated with depression. However, EPA markedly outperformed DHA in curbing microglial activation and correcting imbalances in immune response. Overall, our research supports the understanding of EPA as a particularly promising option in the fight against depression.
Through our analysis, we observed that DPA not only improved the effectiveness of exosomes but also significantly alleviated symptoms of depression. The therapy showed a remarkable ability to suppress the harmful activation of specific immune cells in the brain, known as M1 microglia, which are often linked to inflammation. Additionally, DPA helped restore levels of important neurotransmitters, including serotonin and dopamine.
Furthermore, in laboratory tests, the exosomes treated with DPA demonstrated better protective effects against cell death and inflammation-induced damage. Mechanistically, this positive outcome was attributed to DPA’s ability to enhance the expression of a particular microRNA that plays a role in reducing inflammation pathways.
Overall, our findings suggest that DPA treatment combined with exosomes not only addresses neuroinflammation but also promotes overall brain health. This makes it a promising avenue for developing more effective depression treatments.
Throughout three weeks, we monitored the behavior of these mice, some receiving an EPA and docosahexaenoic acid (DHA) supplement while others did not. We found that the stressed mice given the omega-3 supplement showed no signs of depression or anxiety, which was a stark contrast to the vehicle group that did experience these symptoms.
Additionally, the study indicated that the omega-3 supplementation helped in mitigating the stress responses, such as reduced inflammation in the brain and changes in metabolism. This finding suggests that omega-3 fatty acids could have a therapeutic potential for addressing juvenile depression.
Overall, our observation sheds light on the significant benefits of incorporating eicosapentaenoic acid into diets, especially for young individuals facing mental health challenges.
The findings revealed that higher plasma levels of DHA were linked to a lower risk of developing depressive disorders compared to those with lower levels. Specifically, we observed a hazard ratio of 0.80 for individuals with the highest DHA levels, indicating a significant protective effect. This trend extended to anxiety disorders as well, suggesting that increasing our intake of omega-3 PUFAs might be a reachable goal for enhancing mental health.
Additionally, we noted that higher levels of DHA were also related to a decrease in adverse psychological symptoms. Encompassing the impact on brain health, we incorporated neuroimaging data from nearly 8,800 participants to investigate white matter microstructures, further supporting the link between omega-3 PUFAs like DHA and overall mental well-being.
The evidence we gathered underscores the importance of considering omega-3 PUFAs, particularly DHA, as a promising nutritional approach for helping to prevent and manage depression in older adults.
Throughout the study, these mice received either a supplement containing both DHA and eicosapentaenoic acid (EPA) or a placebo. The results were quite promising! Mice treated with the omega-3 supplement showed significantly fewer signs of depression and anxiety compared to those that received the placebo. This included a noticeable improvement in behaviors related to pleasure and reduced anxiety.
Additionally, the omega-3 treatment seemed to have a positive effect on hormone levels and inflammatory markers in the brain, indicating that the anti-inflammatory properties of DHA could be part of its effectiveness. Overall, our findings suggest that omega-3 fatty acids might hold potential as a therapeutic option for addressing juvenile depression.
User Reviews
- All Reviews
- Positive Reviews
- Negative Reviews
Frequently Asked Questions
Depression is a common and serious mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in activities that were once enjoyable. It can affect anyone, regardless of age, gender, or background, and it goes beyond just feeling down; it can interfere significantly with daily life, impacting relationships, work performance, and overall well-being. Symptoms of depression may include changes in appetite or weight, sleep disturbances, fatigue, difficulty concentrating, and thoughts of worthlessness or suicide.
The causes of depression are complex and may involve a combination of genetic, biological, environmental, and psychological factors. While it's a serious condition that can be debilitating, the good news is that it is treatable. Various treatment options are available, including therapy, medication, lifestyle changes, and support groups. If you or someone you know is struggling with depression, seeking help from a healthcare professional is a crucial step toward recovery.
Omega-3 fish oil is a nutritional supplement derived from the fatty tissues of fish, particularly fatty fish like salmon, mackerel, and sardines. It is rich in omega-3 fatty acids, which are essential fats that the body cannot produce on its own. The most significant types of omega-3s found in fish oil are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both of which are known for their numerous health benefits. These include reducing inflammation, supporting heart health, and promoting brain function.
Incorporating omega-3 fish oil into your diet can be beneficial if you don’t consume enough fish regularly. Many health experts recommend oily fish as a part of a balanced diet due to their high omega-3 content. For those who find it difficult to include fish in their meals, fish oil supplements can offer a convenient alternative, providing the same essential fatty acids in concentrated form. However, it’s essential to choose high-quality supplements that are third-party tested for purity and potency to avoid contaminants such as heavy metals or other toxins that can impact health.
The relationship between Omega-3 fish oil and depression has garnered considerable interest over the years, and some studies suggest that Omega-3 fatty acids may have a beneficial effect on mood and mental well-being. Omega-3s, particularly EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), are thought to contribute to brain health and may play a role in the regulation of neurotransmitters such as serotonin and dopamine, which are often linked to mood disorders. Some clinical trials have indicated that supplementation with Omega-3s can lead to reductions in depressive symptoms for certain individuals, particularly in those with major depressive disorder.
However, it's essential to understand that while Omega-3 fish oil can be a useful part of an overall treatment plan, it is not a panacea for depression. Responses to supplementation can vary from person to person, and more research is needed to establish precise recommendations. It is always advisable for individuals experiencing depression to consult with a healthcare professional to develop a comprehensive treatment approach tailored to their specific needs, which may include therapy, lifestyle changes, and possibly dietary supplements like Omega-3 fish oil.
Based on user reviews, individuals taking fish oil supplements for depression typically report a variety of timelines when it comes to noticing significant results. Users have shared positive experiences regarding improvements in their mental health and cognitive function, often citing benefits felt within a few weeks of consistent use. While specific timelines are not universally mentioned, many seem to notice changes in their mood and overall well-being after taking the supplement regularly. For instance, one user noted that their "permanent depression" has lifted, highlighting an effective transition, although the duration of their use isn't specified (Read Review). Another user similarly emphasized improvements in cognitive abilities, suggesting that noticeable benefits can emerge relatively quickly after incorporating the supplement into one’s daily regimen (Read Review).
Omega-3 fish oil, particularly eicosapentaenoic acid (EPA), has shown potential in alleviating depression symptoms, based on a variety of studies. For older adults, a comprehensive review of 31 randomized controlled trials suggested that omega-3 treatments resulted in a moderate decrease in depression scores, highlighting its relevance for this demographic [1]. Furthermore, in studies focused on specific populations such as children and adolescents, while the results were variable, some showed promising outcomes—especially when omega-3 was administered alongside psychotherapy [15].
Moreover, research utilizing animal models has demonstrated that EPA can mitigate stress-induced neuronal damage and inflammation, both of which are linked to depressive behaviors [2]. Similarly, larger epidemiological studies have indicated a consistent correlation between higher levels of omega-3s and a reduced risk of depression [36]. However, it’s crucial to note that while these findings hint at the benefits of omega-3 supplementation in treating depression, more rigorous and longitudinal studies are necessary to solidify its role and efficacy across different populations and conditions [40].
Users have reported a range of improvements in symptoms after taking fish oil supplements, particularly concerning mental health and cognitive function. Notable experiences include significant relief from depression, with one user stating that it helped lift their "permanent depression," marking a substantial transition in their mental well-being (Read Review). Several others echoed this sentiment, describing enhancements in cognitive abilities and overall health, alongside improvements in skin quality and gastrointestinal well-being (Read Review) (Read Review).
Moreover, users have highlighted the anti-inflammatory benefits and the potential for reduced anxiety, which complements the therapeutic effects on mood. One individual specifically noted the product's efficacy in addressing inflammation while supporting mental health, suggesting a comprehensive impact on both physical and emotional symptoms (Read Review) (Read Review). Overall, while individual results can vary, many users have experienced positive changes and credited the supplement with contributing to their improved quality of life.
Users have reported positive experiences when combining this fish oil supplement with other products aimed at alleviating depression. Several individuals noted its effectiveness in reducing symptoms of depression while also addressing other health aspects, such as cognitive function and inflammation. For example, one user highlighted that taking this Omega-3 regularly has aided in lifting their "permanent depression," indicating a strong impact on mental health (Read Review). Another individual mentioned improvements not only in depression but also in cognitive abilities and skin quality, suggesting synergistic benefits when paired with other supplements targeting overall well-being (Read Review).
Moreover, users have suggested that the anti-inflammatory effects of Omega-3 may complement other supplements they are taking, enhancing overall mental health support. One reviewer specifically noted that the supplement helps reduce anxiety and inflammation, showcasing its multifaceted benefits (Read Review). Hence, it appears that many users view the fish oil not only as a stand-alone aid for depression but also as a valuable component in a broader regimen of health improvements, potentially leading to noticeable enhancements in mood, cognitive skills, and general health when combined with other supplements.
The optimal dose for Omega-3 Fish Oil, particularly eicosapentaenoic acid (EPA), in treating depression appears to be between 1,000 to 1,500 mg daily for adults, particularly those with mild to moderate depression. Research suggests that doses exceeding 1 gram per day of EPA can lead to significant improvements in depressive symptoms, especially in populations affected by inflammation [19]. In a study focused on Asian patients, the best results were seen with a daily dosage of 1,000 to 1,500 mg over eight weeks, particularly when maintaining a specific balance between EPA and docosahexaenoic acid (DHA) in a ratio of 1:1 to 2:1 [33].
Additionally, it's worth noting that while omega-3 supplementation can have a positive impact on depressive symptoms, the results can vary based on individual nutritional backgrounds and the presence of inflammation [40]. Consequently, while these general dosages offer a guideline, it’s essential for individuals to consult with a healthcare provider to tailor omega-3 supplementation to their specific health needs and conditions.
Interestingly, omega-3 paired with psychoeducational psychotherapy showed notable results, achieving a 91.5% remission rate compared to placebo. This suggests a promising role for omega-3 in treating pediatric depression when combined with specific therapies.
Additionally, EPA demonstrated its ability to lower neuroinflammation linked to depressive behaviors. The findings highlight the potential of EPA as an effective option for managing depression related to inflammation. While further research is needed, these results are promising for its future clinical applications.
The findings revealed that higher plasma levels of DHA were linked to a lower risk of developing depressive disorders compared to those with lower levels. Specifically, we observed a hazard ratio of 0.80 for individuals with the highest DHA levels, indicating a significant protective effect. This trend extended to anxiety disorders as well, suggesting that increasing our intake of omega-3 PUFAs might be a reachable goal for enhancing mental health.
Additionally, we noted that higher levels of DHA were also related to a decrease in adverse psychological symptoms. Encompassing the impact on brain health, we incorporated neuroimaging data from nearly 8,800 participants to investigate white matter microstructures, further supporting the link between omega-3 PUFAs like DHA and overall mental well-being.
The evidence we gathered underscores the importance of considering omega-3 PUFAs, particularly DHA, as a promising nutritional approach for helping to prevent and manage depression in older adults.
However, the results of studies on DHA supplementation have been mixed. While some individuals experienced significant reductions in depressive symptoms, others saw little to no improvement.
We found that various factors could affect these outcomes, such as the amounts of DHA taken, how it compares to other omega-3 fatty acids like EPA, and each person's overall nutritional status. Some researchers even suggest that DHA could be used alongside other treatments for depression.
Despite some promising findings, the differences in study methods and how people respond highlight the need for more research. Establishing clear guidelines on using DHA for depression is essential to ensure consistent and effective treatment options.
Participants who received doses greater than 1 gram per day of EPA showed notable improvements in their depressive symptoms. We also observed that these improvements were linked to increases in beneficial lipid mediators that help reduce inflammation. This suggests that EPA could work as an adjunct treatment, enhancing mood, cognitive functions, and even metabolic health.
Although we see encouraging results, particularly for those with certain types of depression, we acknowledge that more robust research is necessary. Further investigations will help us refine dosing strategies, treatment durations, and identify which patient groups can benefit the most from this therapy. Looking ahead, it will be vital to explore long-term effects and interactions with other treatments as well.
While we found some significant evidence suggesting that omega-3 PUFAs, in general, could be beneficial for people suffering from depression, the specific impact of DHA alone was not isolated. It turned out that there's no stronger effect from omega-3 PUFAs compared to a placebo in terms of response rates, remission, or adverse events. Interestingly, we noted that patients from Asia who experienced mild to moderate depression and took DHA over a period of eight weeks might fare the best if their daily dosage ranged from 1000 to 1500 mg, maintaining a specific ratio of eicosapentaenoic acid (EPA) to DHA.
Overall, we observed that while omega-3s may provide some benefits in treating depression, they do not show superior results compared to a placebo group. This highlights the importance of understanding not just the broader category of omega-3s, but the nuanced roles of individual components like DHA.
References
- Gong H, Su WJ, Deng SL, Luo J, Du ZL, et al. Anti-inflammatory interventions for the treatment and prevention of depression among older adults: a systematic review and meta-analysis. Transl Psychiatry. 2025;15:114. doi:10.1038/s41398-025-03317-3
- Yu Q, Li H, Chen M, Pan Y, Zhou L, et al. GPR120 internalization: a key mechanism for EPA in antidepressant action. Food Funct. 2025;16:2893. doi:10.1039/d5fo00252d
- Dyall SC, Malau IA, Su KP. Omega-3 polyunsaturated fatty acids in depression: insights from recent clinical trials. Curr Opin Clin Nutr Metab Care. 2025;28:66. doi:10.1097/MCO.0000000000001077
- Al Sinani M, Johnson M, Crawford M, Al Maqbali M, Al-Adawi S. Depression and anxiety in the pregnant Omani population in relation to their fatty acid intake and levels. Prostaglandins Leukot Essent Fatty Acids. 2025;204:102668. doi:10.1016/j.plefa.2025.102668
- Wang B, Liu P, Gao X, Yang F, Sun J, et al. Exploring the ameliorative effects of omega-3 fatty acid supplementation on maternal behavioral abnormalities induced by prenatal chronic restraint stress. Behav Brain Res. 2025;483:115458. doi:10.1016/j.bbr.2025.115458
- Raza ML, Hassan ST, Jamil S, Fatima W, Fatima M. Nutritional interventions in depression: The role of vitamin D and omega-3 fatty acids in neuropsychiatric health. Clin Nutr. 2025;45:270. doi:10.1016/j.clnu.2025.01.009
- Faulkner P, Gibson EL, Dyall SC. Long-chain omega-3 polyunsaturated fatty acids are associated with brain connectivity and mood in young adults with subthreshold depression: A preliminary study. Prostaglandins Leukot Essent Fatty Acids. 2025;204:102664. doi:10.1016/j.plefa.2025.102664
- Li Y, Hua L, Ran Q, Gu J, Bao Y, et al. Plasma Polyunsaturated Fatty Acid Levels and Mental Health in Middle-Aged and Elderly Adults. Nutrients. 2024;16. doi:10.3390/nu16234065
- Campisi SC, Zasowski C, Bradley-Ridout G, Schumacher A, Szatmari P, et al. Omega-3 fatty acid supplementation for depression in children and adolescents. Cochrane Database Syst Rev. 2024;11:CD014803. doi:10.1002/14651858.CD014803.pub2
- Wu SK, Yang KJ, Liu WC, Malau IA, Zailani H, et al. The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Nutrients. 2024;16. doi:10.3390/nu16213688
- Jastrzebska J, Frankowska M, Wesołowska J, Filip M, Smaga I. Dietary Intervention with Omega-3 Fatty Acids Mitigates Maternal High-Fat Diet-Induced Behavioral and Myelin-Related Alterations in Adult Offspring. Curr Neuropharmacol. 2025;23:329. doi:10.2174/1570159X23666241014164940
- Chen L, Yang Y, Zhang N, Che H, Wang Z, et al. DHA and EPA alleviate depressive-like behaviors in chronic sleep-deprived mice: Involvement of iron metabolism, oligodendrocyte-lipids peroxidation and the LCN2-NLRP3 signaling axis. Free Radic Biol Med. 2024;225:654. doi:10.1016/j.freeradbiomed.2024.10.298
- Cheng YC, Chen WY, Lin C, Lee SH, Chiu CC, et al. The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial. J Affect Disord. 2025;369:8. doi:10.1016/j.jad.2024.09.129
- Serefko A, Jach ME, Pietraszuk M, Świąder M, Świąder K, et al. Omega-3 Polyunsaturated Fatty Acids in Depression. Int J Mol Sci. 2024;25. doi:10.3390/ijms25168675
- Lam C, Han L, McIntyre RS, Teopiz KM, Cao B. Comparative Efficacy of Omega-3 Fatty Acid with Other Interventions for Depression in Children and Adolescents: A Systematic Review and Network Meta-Analysis. J Child Adolesc Psychopharmacol. 2024;34:282. doi:10.1089/cap.2024.0017
- Carnegie R, Borges MC, Jones HJ, Zheng J, Haycock P, et al. Omega-3 fatty acids and major depression: a Mendelian randomization study. Transl Psychiatry. 2024;14:222. doi:10.1038/s41398-024-02932-w
- Kong L, Zhang Q, Wang H, Xu Y, Xu C, et al. Exploration of the optimized portrait of omega-3 polyunsaturated fatty acids in treating depression: A meta-analysis of randomized-controlled trials. J Affect Disord. 2025. doi:10.1016/j.jad.2025.03.006
- Urata M, Sakurai H, Ueno F, Maruki T, Tada T, et al. Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis. Neuropsychopharmacol Rep. 2025;45:e70008. doi:10.1002/npr2.70008
- Dyall SC, Malau IA, Su KP. Omega-3 polyunsaturated fatty acids in depression: insights from recent clinical trials. Curr Opin Clin Nutr Metab Care. 2025;28:66. doi:10.1097/MCO.0000000000001077
- Faulkner P, Gibson EL, Dyall SC. Long-chain omega-3 polyunsaturated fatty acids are associated with brain connectivity and mood in young adults with subthreshold depression: A preliminary study. Prostaglandins Leukot Essent Fatty Acids. 2025;204:102664. doi:10.1016/j.plefa.2025.102664
- Campisi SC, Zasowski C, Bradley-Ridout G, Schumacher A, Szatmari P, et al. Omega-3 fatty acid supplementation for depression in children and adolescents. Cochrane Database Syst Rev. 2024;11:CD014803. doi:10.1002/14651858.CD014803.pub2
- Wu SK, Yang KJ, Liu WC, Malau IA, Zailani H, et al. The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Nutrients. 2024;16. doi:10.3390/nu16213688
- Lin YW, Cheng SW, Liu WC, Zailani H, Wu SK, et al. Chemogenetic targeting TRPV1 in obesity-induced depression: Unveiling therapeutic potential of eicosapentaenoic acid and acupuncture. Brain Behav Immun. 2025;123:771. doi:10.1016/j.bbi.2024.10.028
- Chen L, Yang Y, Zhang N, Che H, Wang Z, et al. DHA and EPA alleviate depressive-like behaviors in chronic sleep-deprived mice: Involvement of iron metabolism, oligodendrocyte-lipids peroxidation and the LCN2-NLRP3 signaling axis. Free Radic Biol Med. 2024;225:654. doi:10.1016/j.freeradbiomed.2024.10.298
- Li P, Zhang F, Huang C, Zhang C, Yang Z, et al. Exosomes Derived from DPA-treated UCMSCs Attenuated Depression-like Behaviors and Neuroinflammation in a Model of Depression Induced by Chronic Stress. J Neuroimmune Pharmacol. 2024;19:55. doi:10.1007/s11481-024-10154-6
- Cheng YC, Chen WY, Lin C, Lee SH, Chiu CC, et al. The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial. J Affect Disord. 2025;369:8. doi:10.1016/j.jad.2024.09.129
- Serefko A, Jach ME, Pietraszuk M, Świąder M, Świąder K, et al. Omega-3 Polyunsaturated Fatty Acids in Depression. Int J Mol Sci. 2024;25. doi:10.3390/ijms25168675
- Lin YL, Wang CL, Chiang TI. Eicosapentaenoic acid supplementation alleviates pruritus, enhances skin moisture, and mitigates depression in maintenance hemodialysis patients. Front Nephrol. 2024;4:1365809. doi:10.3389/fneph.2024.1365809
- Strekalova T, Radford-Smith D, Dunstan IK, Gorlova A, Svirin E, et al. Omega-3 alleviates behavioral and molecular changes in a mouse model of stress-induced juvenile depression. Neurobiol Stress. 2024;31:100646. doi:10.1016/j.ynstr.2024.100646
- Carnegie R, Borges MC, Jones HJ, Zheng J, Haycock P, et al. Omega-3 fatty acids and major depression: a Mendelian randomization study. Transl Psychiatry. 2024;14:222. doi:10.1038/s41398-024-02932-w
- Lou F, Luo S, Kang N, Yan L, Long H, et al. Oral microbiota dysbiosis alters chronic restraint stress-induced depression-like behaviors by modulating host metabolism. Pharmacol Res. 2024;204:107214. doi:10.1016/j.phrs.2024.107214
- Zhang C, Hou B, Xu Y, Zeng S, Luo X, et al. Association between eicosapentaenoic acid consumption and the risk of depressive symptoms in US adults: Analyses from NHANES 2005-2018. J Affect Disord. 2024;354:62. doi:10.1016/j.jad.2024.03.055
- Kong L, Zhang Q, Wang H, Xu Y, Xu C, et al. Exploration of the optimized portrait of omega-3 polyunsaturated fatty acids in treating depression: A meta-analysis of randomized-controlled trials. J Affect Disord. 2025. doi:10.1016/j.jad.2025.03.006
- Faulkner P, Gibson EL, Dyall SC. Long-chain omega-3 polyunsaturated fatty acids are associated with brain connectivity and mood in young adults with subthreshold depression: A preliminary study. Prostaglandins Leukot Essent Fatty Acids. 2025;204:102664. doi:10.1016/j.plefa.2025.102664
- Huang S, Guo J, Jiang R, Ma K, Lin F, et al. Four-way decomposition of the effects of nutrient supplement and physical exercise on depression among older Chinese: a nationwide cross-sectional analysis. BMC Public Health. 2024;24:3469. doi:10.1186/s12889-024-20995-8
- Li Y, Hua L, Ran Q, Gu J, Bao Y, et al. Plasma Polyunsaturated Fatty Acid Levels and Mental Health in Middle-Aged and Elderly Adults. Nutrients. 2024;16. doi:10.3390/nu16234065
- Wu SK, Yang KJ, Liu WC, Malau IA, Zailani H, et al. The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Nutrients. 2024;16. doi:10.3390/nu16213688
- Chen L, Yang Y, Zhang N, Che H, Wang Z, et al. DHA and EPA alleviate depressive-like behaviors in chronic sleep-deprived mice: Involvement of iron metabolism, oligodendrocyte-lipids peroxidation and the LCN2-NLRP3 signaling axis. Free Radic Biol Med. 2024;225:654. doi:10.1016/j.freeradbiomed.2024.10.298
- Cheng YC, Chen WY, Lin C, Lee SH, Chiu CC, et al. The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial. J Affect Disord. 2025;369:8. doi:10.1016/j.jad.2024.09.129
- Serefko A, Jach ME, Pietraszuk M, Świąder M, Świąder K, et al. Omega-3 Polyunsaturated Fatty Acids in Depression. Int J Mol Sci. 2024;25. doi:10.3390/ijms25168675
- Strekalova T, Radford-Smith D, Dunstan IK, Gorlova A, Svirin E, et al. Omega-3 alleviates behavioral and molecular changes in a mouse model of stress-induced juvenile depression. Neurobiol Stress. 2024;31:100646. doi:10.1016/j.ynstr.2024.100646
- Carnegie R, Borges MC, Jones HJ, Zheng J, Haycock P, et al. Omega-3 fatty acids and major depression: a Mendelian randomization study. Transl Psychiatry. 2024;14:222. doi:10.1038/s41398-024-02932-w
- Wang M, Yan X, Li Y, Li Q, Xu Y, et al. Association between plasma polyunsaturated fatty acids and depressive among US adults. Front Nutr. 2024;11:1342304. doi:10.3389/fnut.2024.1342304
- Chang YY, Ting B, Chen DT, Hsu WT, Lin SC, et al. Omega-3 Fatty Acids for Depression in the Elderly and Patients with Dementia: A Systematic Review and Meta-Analysis. Healthcare (Basel). 2024;12. doi:10.3390/healthcare12050536
- Suneson K, Söderberg Veibäck G, Lindahl J, Tjernberg J, Ståhl D, et al. Omega-3 fatty acids for inflamed depression - A match/mismatch study. Brain Behav Immun. 2024;118:192. doi:10.1016/j.bbi.2024.02.029
- Xue Y, Wang L, Liu T, Zhao T, Xie K, et al. Omega-3 polyunsaturated fatty acids supplementation improves memory in first-diagnosed, drug-naïve patients with depression: Secondary analysis of data from a randomized controlled trial. J Affect Disord. 2024;350:403. doi:10.1016/j.jad.2024.01.149
- Yang Y, Chen L, Zhang N, Zhao Y, Che H, et al. DHA and EPA Alleviate Epileptic Depression in PTZ-Treated Young Mice Model by Inhibiting Neuroinflammation through Regulating Microglial M2 Polarization and Improving Mitochondrial Metabolism. Antioxidants (Basel). 2023;12. doi:10.3390/antiox12122079
